Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) belongs to Healthcare sector. Its weekly performance is 60.43%. On last trading day company shares ended up $3.69. Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) distance from 50-day simple moving average (SMA50) is 40.09%. Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), announced positive final results from a Phase II investigator sponsored clinical trial of OHR-102 (0.2% Squalamine lactate ophthalmic solution) in patients with macular edema secondary to branch (BRVO) and central retinal vein occlusion (CRVO).
Aoxing Pharmaceutical Company, Inc. (NYEMKT:AXN) shares increased 23.74% in last trading session and ended the day at $1.72. AXN Gross Margin is 73.10% and its return on assets is -2.70%. Aoxing Pharmaceutical Company, Inc. (NYSEMKT:AXN) quarterly performance is -7.03%. Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) announced positive results of its Buprenorphine/Naloxone sublingual tablets as a treatment for opioid dependence. This was a registration clinical study evaluating the safety and efficacy of the sublingual tablets in order to gain the final production and marketing clearance by the China Food and Drug Administration (CFDA)
On 13 July, BioScrip, Inc. (NASDAQ:BIOS) shares increased 5.59% and was closed at $3.21. BIOS EPS growth in last 5 year was -28.70%. BioScrip, Inc. (NASDAQ:BIOS) year to date (YTD) performance is -54.08%. An investigation for investors in BioScrip Inc (NASDAQ:BIOS) shares long-term was announced concerning potential wrongdoing by certain directors of BioScrip Inc that caused damages to NASDAQ:BIOS stockholders.
Accuray Incorporated (NASDAQ:ARAY) ended the last trading day at $7.16. Company weekly volatility is calculated as 3.31% and price to cash ratio as 3.78. Accuray Incorporated (NASDAQ:ARAY) showed a weekly performance of 5.14%. Accuray Incorporated (NASDAQ:ARAY) and RaySearch Laboratories AB (publ) announced they have signed a long-term collaboration agreement which will allow Accuray to co-market and offer the RayCare® oncology information system (OIS) which is currently in development at RaySearch. Under the contract, Accuray will have the opportunity to offer RayCare® in several designated major radiation therapy markets, making available a fully-integrated solution with the TomoTherapy® and CyberKnife® System product portfolios.
Clovis Oncology, Inc. (NASDAQ:CLVS) shares increased 5.74% in last trading session and ended the day at $84.61. CLVS return on assets is -26.30%. Clovis Oncology, Inc. (NASDAQ:CLVS) quarterly performance is -3.29%. On 10 July, Clovis Oncology (NASDAQ:CLVS) announced today that the underwriters of its recently announced public offering of its common stock have exercised in full their option to purchase an additional 528,846 shares.